Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cardiovascular diseases. Hallmarks of NAFLD are increased triglyceride accumulation within hepatocytes. Subclinical hypothyroidism (SCH), characterized by an elevated thyrotropin (TSH) level and a normal free thyroxine (T4) level, has recently been demonstrated as a risk factor for NAFLD. Emerging evidence revealed that the prevalence of NAFLD increases steadily with increasing TSH levels. As TSH is the only thyroid function component affected in SCH, it raises the question that whether TSH might also plays an important role in the development of NAFLD. Sterol regulatory element binding protein 1c (SREBP-1c) is a key lipogenic transcription factor, which directly activates the expression of more than 30 genes, dedicated to the synthesis and uptake of fatty acids and triglyceride. Increased SREBP-1c levels were found in patients with histologically diagnosed NAFLD. Our previous study suggested that functional TSH receptor (TSHR) is presented on hepatocyte membrane, through which TSH increases the liver triglyceride content, and ultimately promotes the development of NAFLD. Additionally, our latest reports showed that compared with wild type (Tshr+/+) mice, Tshr-/- mice exhibit a relatively lower degree of liver steatosis and SREBP-1c mRNA expression induced through a high fat diet. Whether SREBP-1c also takes part in the process of TSH regulates hepatic triglyceride and the exact functional mechanisms are still uncertain, and no one once had taken a relative investigation. Therefore, using both in vitro (TSH stimulation on liver cells, interference, blocking or activation of the key molecules) and in vivo (conditionally knockout of liver Tshr gene mouse model, TSHR-RNAi mouse model, thyroid total resection rat model) experiments and the relative key targets intervention approaches, we will elucidate the key molecules and major signaling networks about the effection of TSH on SREBP-1c in the liver, explore the pathophysioligical mechanism of the triglyceride metabolism abnormalities in thyroidal dysfunction situation and further provide newly theoretical evidence for its treatment strategy.
非酒精性脂肪肝(NAFLD)主要特征是肝内甘油三酯蓄积。临床资料显示TSH水平与NAFLD 患病率呈正相关,但机制不明。课题组前期研究发现肝脏表达有生物活性的TSH受体(TSHR);TSH增加肝细胞固醇调节元件结合蛋白-1c(SREBP-1c)的表达和甘油三酯含量;高脂喂养的Tshr基因敲除小鼠肝脏脂肪变减轻。目前关于TSH调节肝脏甘油三酯合成的研究未见国内外报道。本项目以TSH为切入点,围绕调节肝脏甘油三酯合成的关键分子SREBP-1c,应用体内动物(条件性敲除甲状腺Tshr基因、条件性敲除肝脏Tshr基因、SREBP-1c基因敲除、PPARα基因敲除小鼠等多种模型)与体外细胞水平(TSH刺激肝细胞、沉默基因表达及阻断传递等技术)相结合技术手段,阐明TSH通过肝脏TSHR和SREBP-1c介导增加甘油三酯合成的作用及机制,为揭示TSH在NAFLD发生发展中的作用提供新思路。
背景:非酒精性脂肪肝(NAFLD)发生机制已经有大量报道,但是关于临床甲状腺功能减退伴随脂肪肝的发生机制尚未见报道。项目组根据亚临床甲状腺功能减退的特点—促甲状腺激素(TSH)升高,甲状腺激素水平相对正常,对TSH是否调控肝细胞甘油三脂累积开展研究。方法: 建立相关的各种小鼠模型、利用多种原代肝细胞和肝细胞株和分子生物学技术。结果:1. TSH能剂量和时间依赖性地增加肝细胞内脂滴含量;2 体内外实验证实TSH增加甘油三酯代谢相关基因表达改变;3 . SREBP-1c在TSH调节甘油三酯合成中发挥中心作用。4. TSH 通过cAMP/PKA/PPARa 信号通路影响SREBP-1c转录伴随AMPK 活性变化影响SREBP-1c活性。5. 亲环素D(CypD)诱发肝脏线粒体应激与脂质沉积呈正相关。 结论:TSH异常升高通过cAMP/PKA/PPARa 信号通路及伴随AMPK影响SREBP-1c,增加肝脏脂质累积;CypD通过激活线粒体膜孔过度开放,加强 SREBP-1c 转录,诱导甘油三脂合成,诱发非酒精性脂肪肝。
{{i.achievement_title}}
数据更新时间:2023-05-31
祁连山天涝池流域不同植被群落枯落物持水能力及时间动态变化
气相色谱-质谱法分析柚木光辐射前后的抽提物成分
资本品减税对僵尸企业出清的影响——基于东北地区增值税转型的自然实验
氯盐环境下钢筋混凝土梁的黏结试验研究
物联网中区块链技术的应用与挑战
ZBED3通过SREBP-1c促进肝脏甘油三酯蓄积的机制研究
TSH通过ApoB介导增加肝脏VLDL输出的分子机制
Menin通过PPARalpha调节肝脏甘油三酯代谢的分子机制
肝脏生物钟通过USP2-45/PPARα信号通路调控肝脏甘油三酯含量的机制研究